Claims for Patent: 8,747,852

Summary for Patent: 8,747,852

Title:	Methods of treating pterygium
Abstract:	Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.
Inventor(s):	Pham; Randal Tanh Hoang (San Jose, CA)
Assignee:
Application Number:	13/830,819
Patent Claims:	1. A method for treating pterygium recurrence comprising administering to an affected eye of a subject in need of such treatment (1) an anti-VEGF agent; and (2) an anti-inflammatory steroid, thereby treating the pterygium recurrence. 2. The method of claim 1, wherein the anti-VEGF agent is an antibody or small molecule inhibitor of VEGF signaling. 3. The method of claim 1, wherein the anti-VEGF agent is the antibody bevacizumab. 4. The method of claim 3, wherein the amount of bevacizumab administered is about 2.5 mg. 5. The method of claim 1, wherein the anti-VEGF agent is injected at a site of new blood vessel growth in the affected eye. 6. The method of claim 1, wherein the anti-inflammatory steroid is one of prednisolone acetate, difluprednate, and triamcinolone acetonide. 7. The method of claim 1, wherein the anti-inflammatory steroid is administered topically. 8. The method of claim 1, wherein the anti-inflammatory steroid is injected into the affected eye. 9. The method of claim 1, wherein the treatment is performed in conjunction with surgery to remove pterygium. 10. The method of claim 1, wherein the treatment comprises more than one administration of one or both of the anti-VEGF agent and the anti-inflammatory steroid to the affected eye of the subject. 11. The method of claim 1, wherein the anti-VEGF agent is administered at least once before the anti-inflammatory steroid is administered. 12. The method of claim 1, wherein the anti-inflammatory steroid is administered to the affected eye of the subject at least once before the anti-VEGF agent is administered. 13. The method of claim 1, wherein the subject has had pterygium recurrence prior to commencement of the treatment. 14. The method of claim 1, comprising administering (1) an anti-VEGF agent, (2) an anti-inflammatory steroid and (3) a non-steroidal anti-inflammatory drug (NSAID) to the affected eye of the subject. 15. The method of claim 14, wherein the NSAID is selected from the group consisting of diclofenac, ketorolac, bromfenac and nepafenac. 16. The method of claim 14, wherein the NSAID is administered topically. 17. The method of claim 14, wherein the anti-VEGF agent is an antibody or small molecule inhibitor of VEGF signaling. 18. The method of claim 14, wherein the anti-VEGF agent is the antibody bevacizumab. 19. The method of claim 18, wherein the amount of bevacizumab administered is about 2.5 mg. 20. The method of claim 14, wherein the anti-VEGF agent is injected at a site of new blood vessel growth in the affected eye. 21. The method of claim 14, wherein the anti-inflammatory steroid is one of prednisolone acetate, difluprednate, and triamcinolone acetonide. 22. The method of claim 14, wherein the anti-inflammatory steroid is administered topically to or is injected into the affected eye. 23. The method of claim 14, wherein the treatment is performed in conjunction with surgery to remove pterygium. 24. The method of claim 14, wherein the treatment comprises more than one administration of one or more of the anti-VEGF agent, the anti-inflammatory steroid, and the NSAID to the affected eye of the subject. 25. The method of claim 14, wherein the anti-VEGF agent is administered at least once before the anti-inflammatory steroid or the NSAID or both are administered. 26. The method of claim 14, wherein the anti-inflammatory steroid or the NSAID is administered to the affected eye of the subject at least once before the anti-VEGF agent is administered to the affected eye of the subject. 27. The method of claim 14, wherein the anti-inflammatory steroid and the NSAID are each administered to the affected eye of the subject at least once before the anti-VEGF agent is administered. 28. The method of claim 14, wherein the subject has had pterygium recurrence prior to commencement of the treatment. 29. A method for treating pterygium recurrence comprising administering to an affected eye of a subject in need of such treatment at least two administrations of the antibody bevacizumab and at least one administration of an anti-inflammatory steroid, wherein the at least two administrations of the bevacizumab occur on separate days. 30. The method of claim 29, wherein the anti-inflammatory steroid is triamcinolone acetonide.

Details for Patent 8,747,852

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-12-28